Correcting treatment effect for treatment switching in randomized oncology trials with a modified iterative parametric estimation method

被引:9
作者
Zhang, Jin [1 ]
Chen, Cong [1 ]
机构
[1] Merck Res Labs, Biostat & Res Decis Sci, 351 N Sumneytown Pike, Upper Gwynedd, PA 19454 USA
关键词
causal model; non-compliance; overall survival; treatment switching; SURVIVAL; NONCOMPLIANCE; EVEROLIMUS;
D O I
10.1002/sim.6923
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
In randomized oncology trials, patients in the control arm are sometimes permitted to switch to receive experimental drug after disease progression. This is mainly due to ethical reasons or to reduce the patient dropout rate. While progression-free survival is not usually impacted by crossover, the treatment effect on overall survival can be highly confounded. The rank-preserving structural failure time (RPSFT) model and iterative parametric estimation (IPE) are the main randomization-based methods used to adjust for confounding in the analysis of overall survival. While the RPSFT has been extensively studied, the properties of the IPE have not been thoroughly examined and its application is not common. In this manuscript, we clarify the re-censoring algorithm needed for IPE estimation and incorporate it into a method we propose as modified IPE (MIPE). We compared the MIPE and RPSFT via extensive simulations and then walked through the analysis using the modified IPE in a real clinical trial. We provided practical guidance on bootstrap by examining the performance in estimating the variance and confidence interval for the MIPE. Our results indicate that the MIPE method with the proposed re-censoring rule is an attractive alternative to the RPSFT method. Copyright (c) 2016 John Wiley & Sons, Ltd.
引用
收藏
页码:3690 / 3703
页数:14
相关论文
共 21 条
  • [1] Estimating a treatment effect in survival studies in which patients switch treatment
    Branson, M
    Whitehead, J
    [J]. STATISTICS IN MEDICINE, 2002, 21 (17) : 2449 - 2463
  • [2] Carpenter J, 2000, STAT MED, V19, P1141, DOI 10.1002/(SICI)1097-0258(20000515)19:9<1141::AID-SIM479>3.0.CO
  • [3] 2-F
  • [4] Effect of acyclovir on herpetic ocular recurrence using a structural nested model
    Cole, SR
    Chu, H
    [J]. CONTEMPORARY CLINICAL TRIALS, 2005, 26 (03) : 300 - 310
  • [5] EFRON B, 1987, J AM STAT ASSOC, V82, P171, DOI 10.2307/2289144
  • [6] Hinkley D.V, 1997, Bootstrap methods and their application
  • [7] CORRECTING OVERALL SURVIVAL FOR THE IMPACT OF CROSSOVER VIA A RANK-PRESERVING STRUCTURAL FAILURE TIME (RPSFT) MODEL IN THE RECORD-1 TRIAL OF EVEROLIMUS IN METASTATIC RENAL-CELL CARCINOMA
    Korhonen, P.
    Zuber, E.
    Branson, M.
    Hollaender, N.
    Yateman, N.
    Katiskalahti, T.
    Lebwohl, D.
    Haas, T.
    [J]. JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2012, 22 (06) : 1258 - 1271
  • [8] Adjusting Survival Time Estimates to Account for Treatment Switching in Randomized Controlled Trials-an Economic Evaluation Context: Methods, Limitations, and Recommendations
    Latimer, Nicholas R.
    Abrams, Keith R.
    Lambert, Paul C.
    Crowther, Michael J.
    Wailoo, Allan J.
    Morden, James P.
    Akehurst, Ron L.
    Campbell, Michael J.
    [J]. MEDICAL DECISION MAKING, 2014, 34 (03) : 387 - 402
  • [9] Morden J, 2001, BMC MED RES METHODOL, V11, P1
  • [10] Phase 3 Trial of Everolimus for Metastatic Renal Cell Carcinoma Final Results and Analysis of Prognostic Factors
    Motzer, Robert J.
    Escudier, Bernard
    Oudard, Stephane
    Hutson, Thomas E.
    Porta, Camillo
    Bracarda, Sergio
    Grunwald, Viktor
    Thompson, John A.
    Figlin, Robert A.
    Hollaender, Norbert
    Kay, Andrea
    Ravaud, Alain
    [J]. CANCER, 2010, 116 (18) : 4256 - 4265